HeartBeam restructures to license 3D ECG technology
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
The latest update is out from HeartBeam ( (BEAT) ).
On June 18, 2026, HeartBeam announced a strategic reorganization centered on licensing its patented 3D ambulatory ECG signal technology to established partners rather than relying on direct medical device sales. The company is restructuring around focused implementation teams led by founder and president Branislav Vajdic and executive chairman Rich Ferrari, aiming to streamline decision-making, lower costs and accelerate global adoption of its platform for at-risk cardiac patients.
As part of the shake-up, chief executive Robert P. Eno agreed to step down as CEO, board member and principal executive officer effective June 30, 2026, and will move into a consulting role, while Vajdic will become principal executive officer on July 1, 2026, and director Mark Strome resigned from the board on June 18, 2026. The reorganization emphasizes HeartBeam’s push to expand its AI-ready 3D ECG signal beyond arrhythmia assessment toward heart attack detection, tailor the technology to multiple form factors and markets, and pursue distribution through governments, OEMs, device manufacturers, health systems and consumer wearable firms, following recent FDA clearances for its arrhythmia-focused ECG solutions.
The most recent analyst rating on (BEAT) stock is a Buy
with a $2.50 price target.
To see the full list of analyst forecasts on HeartBeam stock,
see the BEAT Stock Forecast page.
Spark’s Take on BEAT Stock
According to Spark, TipRanks’ AI Analyst, BEAT is a Neutral.
The score is held down primarily by poor financial performance (pre-revenue, large ongoing losses, and persistent cash burn with shrinking equity) and a bearish technical setup (price below key moving averages with negative MACD). The earnings call provides partial offset due to extended runway, reduced cash outflow guidance, and operational/clinical progress, but valuation support is limited with negative earnings and no dividend.
To see Spark’s full report on BEAT stock,
click here.
More about HeartBeam
HeartBeam, Inc., listed on Nasdaq as BEAT, is a medical technology company focused on transforming detection and monitoring of critical cardiac conditions. The company has developed a cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG for portable, out-of-clinic use. Its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software gained similar clearance in December 2025.
The platform is designed to deliver clinical-grade, actionable heart data anywhere, helping physicians track cardiac health trends and acute events remotely and direct patients to appropriate care. HeartBeam holds more than 20 issued patents enabling this technology and positions its 3D ECG signal as a high-quality data source that can support both its own solutions and third-party AI platforms in the broader cardiac monitoring ecosystem.
Average Trading Volume: 928,304
Technical Sentiment Signal: Sell
Current Market Cap: $39.42M
For an in-depth examination of BEAT stock, go to TipRanks’ Overview page.
